Temsirolimus in the treatment of renal cell carcinoma associated with Xp11.2 translocation/TFE gene fusion proteins: a case report and review of literature

Xp11.2 translocation renal cell carcinomas (TRCCs) are a rare family of tumors newly recognized by the World Health Organization (WHO) in 2004. These tumors result in the fusion of partner genes to the TFE3 gene located on Xp11.2. They are most common in the pediatric population, but have been recently implicated in adult renal cell carcinoma (RCC) presenting at an early age. TFE3-mediated direct transcriptional upregulation of the Met tyrosine kinase receptor triggers dramatic activation of downstream signaling pathways including the protein kinase B (Akt)/phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways. Temsirolimus is an inhibitor of mammalian target of rapamycin (mTOR) kinase, a component of intracellular signaling pathways involved in the growth and proliferation of malignant cells. Here we present a case of a 22-year old female who has been treated with temsirolimus for her Xp11.2/TFE3 gene fusion RCC.

[1]  Karl J. Dykema,et al.  Renal Translocation Carcinomas: Clinicopathologic, Immunohistochemical, and Gene Expression Profiling Analysis of 31 Cases With a Review of the Literature , 2008, The American journal of surgical pathology.

[2]  M. Peyromaure,et al.  Carcinome rénal associé à une translocation MiTF/TFE : présentation de six cas chez l’adulte jeune , 2008 .

[3]  L. Trusolino,et al.  The Met tyrosine kinase receptor in development and cancer , 2008, Cancer and Metastasis Reviews.

[4]  M. Ladanyi,et al.  Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum , 2007, The American journal of surgical pathology.

[5]  M. Picken,et al.  Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. , 2007, American journal of clinical pathology.

[6]  A. Porras,et al.  Met acts on Mdm2 via mTOR to signal cell survival during development , 2007, Development.

[7]  R. Gemmill,et al.  Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. , 2007, Urology.

[8]  M. Ladanyi,et al.  TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. , 2007, Cancer research.

[9]  A. Pappo,et al.  Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. , 2006, American journal of clinical pathology.

[10]  Antonio Lopez-Beltran,et al.  2004 WHO classification of the renal tumors of the adults. , 2006, European urology.

[11]  F. McGovern,et al.  Renal-cell carcinoma. , 2005, The New England journal of medicine.

[12]  Manuel Hidalgo,et al.  Intracellular signal transduction pathway proteins as targets for cancer therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Poulik,et al.  Pediatric Renal Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions and Clinicopathologic Associations , 2005, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[14]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[15]  R. Bouvier,et al.  Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2: a cytogenetic and morphologic study. , 2003, Cancer genetics and cytogenetics.

[16]  Mark L. Greenberg,et al.  Renal-cell carcinoma in children: a different disorder from its adult counterpart? , 1998, Medical and pediatric oncology.

[17]  P. Camparo,et al.  [Renal carcinoma associated with MiTF/TFE translocation: report of six cases in young adults]. , 2008, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.